Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Increases Purchase Price for Nanosphere

NEW YORK (GenomeWeb) – Luminex announced today that it has raised the purchase price for Nanosphere to $1.70 per share in cash from the $1.35-per-share price it originally offered for the molecular diagnostics developer.

This raises the share-price value of the transaction to approximately $77 million from $58 million.

Molecular diagnostics and life sciences research tools firm Luminex first announced its purchase agreement with Nanosphere in mid-May. At that time, the company also said it would pay or help Nanosphere pay $25 million in debt outstanding as of March 31. The deal was expected to close on or before July 1.

The increase came in response to an unsolicited bid from an unnamed third party, Luminex said. That company offered to buy Nanosphere for $1.50 per share.

Nanosphere's shares have climbed 27 percent to $1.67 in morning trading on the Nasdaq. Luminex's shares are up nearly 2 percent to $20.19.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.